Like many companies, PocketBook uses cookie technology to enhance your user experience, for analytics and marketing purposes that are to show you relevant offers, tailored the best to your interests while running this website and third parties websites. PocketBook respects your privacy rights, thus we kindly ask you to take a moment to enjoy Managing Cookie Preferences Please take a note that strictly necessary cookies are always enabled. If you are happy with the use of all cookie files, just click Ok in this pop-up. To learn more about cookie technology, its benefits and how Pocketbook use it, please go to our Cookie Notice
You can change your cookie settings at any time, using your cookie settings. You can use this page through your account. For more information about cookies and how we use them, please see our cookie notice.
More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.